Menarini’s Nexpovio wins new NICE recommendation

Menarini Stemline has welcomed the publication of final draft guidance from the National Institute for Health and Care Excellence (NICE) recommending the use of Nexpovio (selinexor) alongside bortezomib and dexamethasone, for eligible multiple myeloma patients who have received one or two prior treatments.

This guidance follows recent guidance from the UK-based body recommending Nexpovio, in combination with dexamethasone, for eligible myeloma patients who have had four or more prior treatments.

The recommendations address significant gaps at three critical points in the treatment pathway, meaning hundreds of patients may now be eligible for a treatment that has the potential to delay the progression of this cancer and prolong survival.